Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450146 | 1.00 | NTRK1 (0.85) | NTRK1JAK2 | |
| SCHEMBL932538 | 1.00 | NTRK1 (0.85) | NTRK1JAK2 | |
| SCHEMBL22073625 | 1.00 | NTRK1 (0.85) | NTRK1JAK2 | |
| SCHEMBL24120995 | 0.92 | NTRK1 (0.82) | NTRK1JAK2 | |
| SCHEMBL22073668 | 0.92 | NTRK1 (0.82) | NTRK1JAK2 | |
| SCHEMBL2691801 | 0.92 | NTRK1 (1.00) | NTRK1JAK2 | |
| SCHEMBL2691800 | 0.92 | NTRK1 (1.00) | NTRK1JAK2 | |
| SCHEMBL29794653 | 0.92 | NTRK1 (1.00) | NTRK1JAK2 | |
| SCHEMBL29497124 | 0.91 | NTRK1 (0.72) | NTRK1JAK2 | |
| SCHEMBL29450115 | 0.91 | NTRK1 (0.72) | NTRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4420732-A2 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2024-08-28 | — | — | EP | disclosed |
| EP-3233863-B1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO LTD (KR) | 2024-04-10 | — | — | EP | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| WO-2023083362-A1 | DRUG FOR TREATING TUMORS | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083362-A1 | DRUG FOR TREATING TUMORS | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023055952-A1 | NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) DEGRADING COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-4151635-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2023-03-22 | — | — | EP | disclosed |
| US-20210395256-A1 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8791123-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791123-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791123-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2451812-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2011006074-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011006074-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395256-A1 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | ABL1, LCK, ERBB2 | NTRK1 108/4885JAK2 35/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | NTRK1 8/4885JAK2 143/4885 |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | TXK, FRK, LTK | NTRK1 7/4885JAK2 124/4885 |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | ROS1, ALK, ROR1 | NTRK1 7/4885JAK2 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.